# A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07811037/  
OnCo record `nct07811037` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SGT003 in advanced solid tumours, run by Beijing Sungen Biomedical Technology Co., Ltd, now recruiting.

## Summary

A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07811037 by Beijing Sungen Biomedical Technology Co., Ltd, with 332 participants planned, started 2026-08-17 and due to reach its primary completion in 2028-12. Interventions recorded: SGT003.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07811037
- Phase: 1/2
- Setting: A Multicenter, Dose-Escalation and Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors
- Sponsor: Beijing Sungen Biomedical Technology Co., Ltd
- Enrolled: 332

## Sources

- ClinicalTrials.gov NCT07811037: https://clinicaltrials.gov/study/NCT07811037

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07811037.json